Novo Holdings advances antimicrobial resistance strategy with acquisition of Paratek Pharmaceuticals

/in

Paratek’s successful commercialisation platform to advance novel therapies developed organically and through acquisitions Paratek adds ‘final-mile’ capabilities to AMR efforts COPENHAGEN, September 21, 2023 – With the closing of the acquisition of Paratek Pharmaceuticals, Inc. (“Paratek”), a commercial-stage biopharmaceutical company focused on the development and commercialisation of novel therapies for life-threatening diseases and other public health […]

Read more

Leucid Bio Granted MHRA Clinical Trial Authorisation for Lateral NKG2D CAR T-Cell Therapy LEU011

/in

Company on-track to dose first patient in LEU011 Phase 1/2 AERIAL trial during the fourth quarter of 2023 Lead programme, LEU011 previously awarded an Innovation Passport by MHRA for the treatment of solid tumours expressing NKG2D ligands London, UK – 21 September 2023 – Leucid Bio (“Leucid” or the “Company”), a privately-held biotechnology company pursuing […]

Read more

New cell therapy facility enters fight against chronic diseases

/in

The Novo Nordisk Foundation has committed up to DKK 950 million (EUR 127 million) to establish a world-class facility for the final development steps and upscaling of cell therapies for testing in humans. The Novo Nordisk Foundation Cellerator will fill a critical gap in the Danish cell therapy ecosystem, helping to translate breakthroughs in cell […]

Read more

Poolbeg Pharma plc – Immunomodulator I Patent Portfolio Strengthened

/in

20 September 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that it has received a notice of allowance from the Japanese Patent Office in relation to its Immunomodulator I patent application. Read more…

Read more

Novo Holdings invests in innovative water treatment pioneer, HPNow, as part of €14m round

/in

Copenhagen, Denmark  – Novo Holdings A/S, a leading global life sciences investor, today announces a significant investment in HPNow, a Danish firm pioneering an innovative form of water treatment, alongside the Export and Investment Fund of Denmark (EIFO) and existing investors MatiTech, Evonik Venture Capital and AP Ventures. Read more…

Read more